Agile Therapeutics (AGRX)

Thursday

5:40 AM

ThesisRecent sales growth and strategic partnerships are enhancing investor confidence in Agile Therapeutics' market position.

Revenue Outlook

Metric	FY2023	FY2024E	FY2025E
Revenue	$20M	$32M	$51M
Rev. Growth	+80.0%	+64.7%	+57.8%
EPS	$-6.71	$-0.60	$0.84
EPS Growth	+88.6%	+91.1%	+240%
P/E	—	—	—

★ Analysts see FY2024 revenue reaching $32M — +64.7% growth in a single year.

Why Revenue Could Explode

01Twirla sales increased by 150% in Q1 2026 compared to Q4 2025, indicating strong market adoption.
02Recent partnership with a major pharmacy chain to enhance distribution could expand market reach significantly.
03Regulatory submission for a new contraceptive product expected in Q3 2026 could diversify revenue streams.
04Increased focus on women's health and contraceptive options
05Shift towards non-invasive contraceptive methods
06Sales growth of Twirla driven by market penetration and physician adoption
07Regulatory approvals for new contraceptive products
08Partnerships or collaborations that expand distribution channels

FY2023 Snapshot

Revenue: $20M
Rev. Growth: +80.0%
Gross Margin: 54.2%
Op. Margin: -101%
Net Margin: -73.8%
Net Income: $-14M
NI Growth: +43.1%
EPS: $-6.71

My Notes

"Our recent performance reflects a strong demand for Twirla and our commitment to expanding access."
Moat: Agile's unique drug delivery system provides a competitive edge, but it faces significant competition from established players.
growth - Investors looking for high-growth potential in the healthcare sector, particularly in women's health.
minimal - Agile Therapeutics is not significantly affected by interest rates as it does not rely heavily on debt financing.
Watch on earnings: Sales growth rate of Twirla, Market penetration percentage, Gross margin percentage.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $32M to $51M as twirla sales increased by 150% in q1 2026 compared to q4 2025, indicating strong market adoption.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Writing up the research noteFirst read for a new ticker takes about 20-30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.